Campbell & Co Investment Adviser’s Pacific Biosciences PACB Stock Holding History

Campbell & Co Investment Adviser’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-84,454	Closed	-$317K	–	1275
2024 Q1	$317K	Buy	84,454 +44,839	+113%	+$263K	0.03%	883
2023 Q4	$389K	Sell	39,615 -11,857	-23%	-$97K	0.04%	825
2023 Q3	$430K	Buy	+51,472	New	+$588K	0.05%	585
2022 Q2	–	Sell	-13,176	Closed	-$120K	–	860
2022 Q1	$120K	Buy	+13,176	New	+$152K	0.03%	659
2021 Q3	–	Sell	-10,000	Closed	-$350K	–	721
2021 Q2	$350K	Buy	+10,000	New	+$291K	0.14%	265

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Campbell & Co Investment Adviser's PACB Position: Q2 2024 in Review

Campbell & Co Investment Adviser sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 84,454 shares — an estimated $317K sold.

Campbell & Co Investment Adviser first reported a position in PACB in Q2 2021 and held it in 5 quarters. The position peaked at $430K in Q3 2023. 228 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

Campbell & Co Investment Adviser reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
Campbell & Co Investment Adviser sold 84,454 Pacific Biosciences shares in Q2 2024, an estimated $317K.
Campbell & Co Investment Adviser first reported a position in Pacific Biosciences in Q2 2021 and held it in 5 quarters.
Campbell & Co Investment Adviser's Pacific Biosciences position peaked at $430K in Q3 2023.
228 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2024, filed 13 Aug 2024.